Multiple myeloma: cell therapy breakthroughs in blood cancers

Logo

Multiple myeloma: cell therapy breakthroughs in blood cancers

Challenges in multiple myeloma treatment

Multiple myeloma arises from the malignant proliferation of plasma cells and impacts the architecture of bone marrow. It affects mostly the elderly and accounts for around 10% of hematological cancers.1 Today’s treatments, including chemotherapy followed by autologous hematopoietic stem cell transplantation (HSCT), significantly increase patient survival time, although all multiple myeloma patients relapse.1, 2

CAR T cell therapies targeting BCMA deliver high rates of complete remission.2, 3 However, many treated patients relapse due to antigen escape and pressure from the tumor microenvironment on the function and persistence of the CAR T cells.2 The therapies also increase the risk of serious inflammatory side effects, and the resulting plasma cell depletion exposes patients to infections.4 Finally, difficulties in scaling manufacturing and distribution limit the availability of anti-BCMA CAR T cell therapies.5

Aiming for long-term remission of multiple myeloma

Several studies aim to reduce relapse using dual-targeting CAR T cells against BCMA and other plasma cell markers like CD38, CD138, CD19, GPRC5D, or SLAMF7/CD319.2 Armoring CAR T cells to increase their potency or combining them with other immunostimulatory drugs may help overcome the immunosuppression of the tumor microenvironment.2

Innate T cells (NK cells, γδ T cells) designed as allogeneic therapies may provide quicker access to treatment. Manufactured from healthier starting cells, they might also show greater potency and response duration.6

Enhancing potency and duration of cell therapies for multiple myeloma

Miltenyi Biotec offers products and services to support clinicians in exploring ways to improve treatment options for multiple myeloma. Therapeutic approaches using NK or γδ T cells, dual-targeting, or other next-generation constructs, armoring, and combination strategies with HSCT offer opportunities to boost the potency, persistence, and availability of life-changing cell therapies.7,8

Expanding availability of cell therapies for multiple myeloma

Clinicians actively seek ways to reduce the manufacturing and distribution expenses associated with cell therapies. Miltenyi Biotec solutions support key strategies like relocating cell manufacturing to the point of care, which streamlines logistics and reduces manufacturing costs.7,8

Miltenyi Biotec solutions in the field

From instruments and software to reagents and protocols, Miltenyi Biotec supports clinicians with solutions designed to automate and standardize the manufacture and analysis of cell and gene therapies. The following presentation and publications illustrate how our solutions are implemented in myeloma clinical research.

Recorded talk

Academic model for CAR T development in multiple myeloma: clinical results with ARI0002h and future plans

Prof. Carlos Fernández de Larrea, Hematologist and Principal Investigator at Hospital Clínic Barcelona, Spain, presents the development and clinical results of ARI0002h, an academic BCMA-directed CAR T cell therapy for relapsed/refractory multiple myeloma. Developed at Hospital Clínic de Barcelona, ARI0002h has shown promising efficacy and safety in a multicenter clinical trial conducted across Spain. This talk will highlight how academic CAR T initiatives like ARI0002h can offer accessible, effective treatment options in settings where commercial CAR T therapies are limited by cost or availability.

Would you like to hear more from your peers?

Publication

Long-term follow-up of ARI0002h (cesnicabtagene autoleucel), an academic point-of-care B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell strategy: activity and safety after fractionated initial therapy and booster dose in 60 patients with relapsed/refractory multiple myeloma (RRMM).

Fernandez de Larrea, C. et al. (2024) J. Clin. Oncol. 42: suppl.7544.

A multicenter study examined the fractionated and booster administration of an anti-BCMA CAR T cell therapy produced at the point of care. Results from patients with heavily treated multiple myeloma indicate a deep and sustained response, with low toxicity and a confirmed safety profile.

View other indications or reach out to our team

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. For complete regulatory notes, please click here.

You have previously chosen International as your location.
What do you want to do?